AbbVie Inc (ABBV)
$257.12-0.40%previous session's close (28 Aug 2026) — awaiting today's first price update
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Skyrizi and Rinvoq drive growth; Q2 miss and acquisition dilute near-term earnings despite strong cash flow.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvi…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $434.8B
Recent dividends
- 15 Jul 2026$1.73
- 15 Apr 2026$1.73
- 16 Jan 2026$1.73
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across AbbVie Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free